TherapeuticsMD, Inc.
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
TXMD$1.74+3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(Unaudited - in thousands, except per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Revenue, net: | ||||
| License revenue | $784 | $547 | $2,129 | $1,094 |
| Operating expenses: | ||||
| General and administrative | 1,518 | 1,585 | 4,560 | 4,884 |
| Impairment of long-lived assets (Note 4) | — | — | — | 1,261 |
| Write-off of patents and trademarks | 32 | — | 120 | — |
| Depreciation and amortization | 96 | 96 | 287 | 409 |
| Total operating expenses | 1,646 | 1,681 | 4,967 | 6,554 |
| Loss from operations | (862) | (1,134) | (2,838) | (5,460) |
| Other income (expense): | ||||
| Interest expense and other financing costs | (3) | (3) | (7) | (8) |
| Sublease income | 534 | 275 | 1,320 | 1,019 |
| Miscellaneous income | 381 | 295 | 1,452 | 2,023 |
| Total other income, net | 912 | 567 | 2,765 | 3,034 |
| Income (loss) from continuing operations before income taxes | 50 | (567) | (73) | (2,426) |
| Income tax benefit | — | — | 32 | — |
| Income (loss) from continuing operations, net of income taxes | 50 | (567) | (41) | (2,426) |
| Income (loss) from discontinued operations, net of income taxes | 102 | (42) | 91 | (7) |
| Net Income (loss) | $152 | $(609) | $50 | $(2,433) |
| Net Income (loss) per common share, basic and diluted: | ||||
| Continuing operations | 0.00 | (0.05) | (0.00) | (0.21) |
| Discontinued operations, net | 0.01 | (0.00) | 0.01 | (0.00) |
| Net Income (loss) per common share, basic and diluted | $0.01 | $(0.05) | $0.00 | $(0.21) |
| Weighted average common shares, basic | 11,574 | 11,532 | 11,567 | 11,532 |
| Weighted average common shares, diluted | 11,574 | 11,532 | 11,567 | 11,532 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.